Payment overview · 2025
General Payments
$1,138.29
61 reported records · 19 companies
Healthcare provider profile · identity verified
Garry Todd Davis, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · COMANCHE, TX · NPI 1699748434
Verified facts
What the public records show
CMS Open Payments records show Garry Todd Davis, D.O. received $1,138.29 in general payments during 2025 across 61 reported records.
Amgen Inc. accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $273.45 | 24.0% | 17 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $170.35 | 15.0% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $131.17 | 11.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $126.18 | 11.1% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $57.73 | 5.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.32 | 4.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.96 | 4.6% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.97 | 3.4% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.88 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.16 | 2.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.62 | 2.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.06 | 2.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.56 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.19 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.10 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.45 | 1.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.16 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.14 | 1.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.84 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,138.29 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $184.49 | 11 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $167.96 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $131.17 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $131.17 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $126.18 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $84.47 | 5 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $57.73 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.32 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.96 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $38.97 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $31.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $28.62 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.02 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.76 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 18 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 442 | 91 |
| Gabapentin | Gabapentin | 439 | 94 |
| Potassium Chloride | Potassium Chloride | 390 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 374 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 360 | 93 |
| Furosemide | Furosemide | 293 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 269 | 67 |
| Lisinopril | Lisinopril | 257 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 65 |
| Simvastatin | Simvastatin | 225 | 53 |
| Metformin Hcl | Metformin Hcl | 209 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 202 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 185 | 49 |
| Meloxicam | Meloxicam | 181 | 45 |
| Losartan Potassium | Losartan Potassium | 177 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 38 |
| Alprazolam | Alprazolam | 162 | 29 |
| Omeprazole | Omeprazole | 159 | 41 |
| Mounjaro | Tirzepatide | 135 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 133 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 34 |
| Eliquis | Apixaban | 125 | 22 |
| Celecoxib | Celecoxib | 119 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 21 |
| Tramadol Hcl | Tramadol Hcl | 105 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 101 | 66 |
| Donepezil Hcl | Donepezil Hcl | 100 | 18 |
| Glipizide | Glipizide | 98 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 24 |
| Sertraline Hcl | Sertraline Hcl | 92 | 21 |
| Montelukast Sodium | Montelukast Sodium | 89 | 18 |
| Carvedilol | Carvedilol | 87 | 21 |
| Baclofen | Baclofen | 85 | 17 |
| Lorazepam | Lorazepam | 85 | 18 |
| Pregabalin | Pregabalin | 85 | 14 |
| Ezetimibe | Ezetimibe | 84 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 82 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 17 |
| Allopurinol | Allopurinol | 76 | 15 |
| Prednisone | Prednisone | 70 | 22 |
| Trazodone Hcl | Trazodone Hcl | 68 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 67 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 17 |
| Methocarbamol | Methocarbamol | 63 | 26 |
| Metolazone | Metolazone | 63 | 17 |
| Ozempic | Semaglutide | 63 | 11 |
| Cefdinir | Cefdinir | 62 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 60 | 13 |
| Buspirone Hcl | Buspirone Hcl | 57 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 37 |
| Primidone | Primidone | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Methotrexate | Methotrexate Sodium | 44 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 35 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 18 |
| Finasteride | Finasteride | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 36 | 12 |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 26 |
| Nystatin | Nystatin | 34 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 26 |
| Azithromycin | Azithromycin | 32 | 26 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 25 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Amoxicillin | Amoxicillin | 28 | 25 |
| Famotidine | Famotidine | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 18 |
| Fluconazole | Fluconazole | 27 | 14 |
| Novolin R | Insulin Regular, Human | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 17 |
| Methimazole | Methimazole | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 19 |
| Cilostazol | Cilostazol | 22 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 22 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,138.29 · 61 records | Amgen Inc. | EVENITY, FARXIGA, FREESTYLE LIBRE, Fluad, Flucelvax, JOURNAVX, KEVEYIS, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, Veozah, YUPELRI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error